The value of Californian biotech Akero Therapeutics (Nasdaq: AKRO) could double on Tuesday, with its shares already up by 89% in pre-market trading.
This comes after the presentation of results on the company’s lead product candidate efruxifermin (EFX) that suggest it could potentially be a foundational monotherapy for patients with non-alcoholic steatohepatitis (NASH).
"Among the strongest efficacy results reported in NASH to date"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze